Skip to main content
. 2021 Dec 23;15:103–119. doi: 10.1016/j.bioactmat.2021.11.032

Fig. 3.

Fig. 3

In vivo biocompatibility assessment. (A) Representative images of tissue sections staining GFAP and CD68 from different groups at 2 weeks after SCI. (B) Quantitative analysis of CD68+ cells. (C) Immunofluorescence images of Iba-1/GFAP+ cells in different groups at 2 weeks post-surgery. (D) Fluorescence quantitative analysis of Iba-1+ cells. (E) Representative images of GFAP and Laminin immunostaining of the spinal cord at 6 weeks after injury. (F) Quantitative data of relative intensities of Laminin+ fibroblast scar. (G) Representative images of GFAP and Fibronectin immunostaining of the spinal cord at 6 weeks after injury. (H) Quantitative data of relative intensities of Fibronectin+ fibroblast scar at the lesion site.